TransOral Pharmaceuticals

TransOral Pharmaceuticals was a specialty pharmaceutical company focused on the development of novel formulations of proven drug compounds using proprietary sublingual delivery technology. The company's primary focus was on central nervous system disorders, most notably insomnia and migraine. Its lead product, Intermezzo (zolpidem tartrate sublingual tablet), was designed specifically for middle-of-the-night awakening, providing a rapid onset of action and a shorter duration of effect to avoid morning grogginess. TransOral was acquired by Purdue Pharma in 2009, which subsequently brought Intermezzo to market following FDA approval.